Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-1195 in Multiple Sclerosis
NCT06735248Phase 2Recruiting
- Sponsor
- Moderna Inc
- Start
- Apr 2025
- Primary completion
- Jan 2029
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 3
01
Overview
A Phase 2 trial of mRNA-1195 in multiple sclerosis (MS), sponsored by Moderna Inc. Started Apr 2025; status: recruiting.
02
Drugs
mRNA-1195
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT06735248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06735248.